5:25 PM ET
10-Q
Financial Results
Revelation Biosciences Q3 2026 Results: Net Loss of $3.32M, Loss Widens
Revelation Biosciences reported a net loss of $9.6 million for the nine months ended September 30, 2026, compared to $6.4 million in the prior year, driven by increased R&D and G&A expenses. The company maintains a cash balance of $9.1 million and expressed substantial doubt about its ability to continue as a going concern without additional capital.
- Key figure
- Net loss $3.32M